Malignant Infantile Osteopetrosis (MIOP), also known as autosomal recessive osteopetrosis, is a rare genetic disorder that ...

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell ...

According to a recent market analysis, the dental composites market is projected to grow at a CAGR of 8.6% from 2024 to ...

The global industry was valued at US$ 3.5 Bn in 2023 and is projected to cross US$ 7.4 Bn by 2034, growing at a CAGR of 7.3% ...

The 39th PM Society Awards, supported by headline sponsor Avalere Health, were held on 14th March, 2025, at the JW Marriott Grosvenor House London. The industry came together for this prestigious ...

The global pulse lavage market is poised for significant expansion, with market sales projected to surge to USD 785 million by 2032, up from USD 356.9 million in 2022, reflecting a robust CAGR of 8.2% ...

High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical ...

The global abdominal closure systems market is set for steady expansion over the next decade, driven by advancements in surgical procedures and increasing demand for improved wound closure solutions.

Anocca AB, a leading T-cell immunotherapy company, announces the authorisation of its Clinical Trial Application (CTA) from the regulatory authorities in four European countries under the European ...

AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme™ platform technology. Under the terms of the agreement, AstraZeneca ...

Onctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces the appointments of Elizabeth Holt as Chief Business Officer (CBO) and Dr Mark ...

Novo Nordisk’s two-year suspension from the Association of the British Pharmaceutical Industry (ABPI) for serious breaches of the ABPI Code of Practice has come to an end [1]. Novo Nordisk’s return to ...